Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Antiretroviral Program Associated with Reduction in Untreated Prevalent Tuberculosis in a South African Township</title><author><name sortKey="Middelkoop, Keren" sort="Middelkoop, Keren" uniqKey="Middelkoop K" first="Keren" last="Middelkoop">Keren Middelkoop</name><affiliation><nlm:aff id="d31e123">Desmond Tutu HIV Centre, Institute of Infectious Diseases & Molecular Medicine, University of Cape Town, Cape Town, South Africa;</nlm:aff></affiliation><affiliation><nlm:aff id="d31e123">Department of Medicine, University of Cape Town, Cape Town, South Africa;</nlm:aff></affiliation></author><author><name sortKey="Bekker, Linda Gail" sort="Bekker, Linda Gail" uniqKey="Bekker L" first="Linda-Gail" last="Bekker">Linda-Gail Bekker</name><affiliation><nlm:aff id="d31e123">Desmond Tutu HIV Centre, Institute of Infectious Diseases & Molecular Medicine, University of Cape Town, Cape Town, South Africa;</nlm:aff></affiliation><affiliation><nlm:aff id="d31e123">Department of Medicine, University of Cape Town, Cape Town, South Africa;</nlm:aff></affiliation></author><author><name sortKey="Myer, Landon" sort="Myer, Landon" uniqKey="Myer L" first="Landon" last="Myer">Landon Myer</name><affiliation><nlm:aff id="d31e123">Centre for Infectious Diseases Epidemiology & Research, School of Public Health & Family Medicine, University of Cape Town, Cape Town, South Africa;</nlm:aff></affiliation><affiliation><nlm:aff id="d31e123">International Centre for AIDS Care and Treatment Programs, and Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York;</nlm:aff></affiliation></author><author><name sortKey="Whitelaw, Andrew" sort="Whitelaw, Andrew" uniqKey="Whitelaw A" first="Andrew" last="Whitelaw">Andrew Whitelaw</name><affiliation><nlm:aff id="d31e123">National Health Laboratory Service, Cape Town, South Africa;</nlm:aff></affiliation><affiliation><nlm:aff id="d31e123">Division of Medical Microbiology, Department of Clinical Laboratory Sciences, University of Cape Town, Cape Town, South Africa;</nlm:aff></affiliation></author><author><name sortKey="Grant, Alison" sort="Grant, Alison" uniqKey="Grant A" first="Alison" last="Grant">Alison Grant</name><affiliation><nlm:aff id="d31e123">London School of Hygiene and Tropical Medicine, London, United Kingdom;</nlm:aff></affiliation></author><author><name sortKey="Kaplan, Gilla" sort="Kaplan, Gilla" uniqKey="Kaplan G" first="Gilla" last="Kaplan">Gilla Kaplan</name><affiliation><nlm:aff wicri:cut="; and" id="d31e123">Laboratory of Mycobacterial Immunity and Pathogenesis, the Public Health Research Institute, University of Medicine and Dentistry of New Jersey, Newark, New Jersey</nlm:aff></affiliation></author><author><name sortKey="Mcintyre, James" sort="Mcintyre, James" uniqKey="Mcintyre J" first="James" last="Mcintyre">James Mcintyre</name><affiliation><nlm:aff id="d31e123">Anova Health Institute, Johannesburg, South Africa</nlm:aff></affiliation></author><author><name sortKey="Wood, Robin" sort="Wood, Robin" uniqKey="Wood R" first="Robin" last="Wood">Robin Wood</name><affiliation><nlm:aff id="d31e123">Desmond Tutu HIV Centre, Institute of Infectious Diseases & Molecular Medicine, University of Cape Town, Cape Town, South Africa;</nlm:aff></affiliation><affiliation><nlm:aff id="d31e123">Department of Medicine, University of Cape Town, Cape Town, South Africa;</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">20558626</idno><idno type="pmc">2970849</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2970849</idno><idno type="RBID">PMC:2970849</idno><idno type="doi">10.1164/rccm.201004-0598OC</idno><date when="2010">2010</date><idno type="wicri:Area/Pmc/Corpus">001478</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001478</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Antiretroviral Program Associated with Reduction in Untreated Prevalent Tuberculosis in a South African Township</title><author><name sortKey="Middelkoop, Keren" sort="Middelkoop, Keren" uniqKey="Middelkoop K" first="Keren" last="Middelkoop">Keren Middelkoop</name><affiliation><nlm:aff id="d31e123">Desmond Tutu HIV Centre, Institute of Infectious Diseases & Molecular Medicine, University of Cape Town, Cape Town, South Africa;</nlm:aff></affiliation><affiliation><nlm:aff id="d31e123">Department of Medicine, University of Cape Town, Cape Town, South Africa;</nlm:aff></affiliation></author><author><name sortKey="Bekker, Linda Gail" sort="Bekker, Linda Gail" uniqKey="Bekker L" first="Linda-Gail" last="Bekker">Linda-Gail Bekker</name><affiliation><nlm:aff id="d31e123">Desmond Tutu HIV Centre, Institute of Infectious Diseases & Molecular Medicine, University of Cape Town, Cape Town, South Africa;</nlm:aff></affiliation><affiliation><nlm:aff id="d31e123">Department of Medicine, University of Cape Town, Cape Town, South Africa;</nlm:aff></affiliation></author><author><name sortKey="Myer, Landon" sort="Myer, Landon" uniqKey="Myer L" first="Landon" last="Myer">Landon Myer</name><affiliation><nlm:aff id="d31e123">Centre for Infectious Diseases Epidemiology & Research, School of Public Health & Family Medicine, University of Cape Town, Cape Town, South Africa;</nlm:aff></affiliation><affiliation><nlm:aff id="d31e123">International Centre for AIDS Care and Treatment Programs, and Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York;</nlm:aff></affiliation></author><author><name sortKey="Whitelaw, Andrew" sort="Whitelaw, Andrew" uniqKey="Whitelaw A" first="Andrew" last="Whitelaw">Andrew Whitelaw</name><affiliation><nlm:aff id="d31e123">National Health Laboratory Service, Cape Town, South Africa;</nlm:aff></affiliation><affiliation><nlm:aff id="d31e123">Division of Medical Microbiology, Department of Clinical Laboratory Sciences, University of Cape Town, Cape Town, South Africa;</nlm:aff></affiliation></author><author><name sortKey="Grant, Alison" sort="Grant, Alison" uniqKey="Grant A" first="Alison" last="Grant">Alison Grant</name><affiliation><nlm:aff id="d31e123">London School of Hygiene and Tropical Medicine, London, United Kingdom;</nlm:aff></affiliation></author><author><name sortKey="Kaplan, Gilla" sort="Kaplan, Gilla" uniqKey="Kaplan G" first="Gilla" last="Kaplan">Gilla Kaplan</name><affiliation><nlm:aff wicri:cut="; and" id="d31e123">Laboratory of Mycobacterial Immunity and Pathogenesis, the Public Health Research Institute, University of Medicine and Dentistry of New Jersey, Newark, New Jersey</nlm:aff></affiliation></author><author><name sortKey="Mcintyre, James" sort="Mcintyre, James" uniqKey="Mcintyre J" first="James" last="Mcintyre">James Mcintyre</name><affiliation><nlm:aff id="d31e123">Anova Health Institute, Johannesburg, South Africa</nlm:aff></affiliation></author><author><name sortKey="Wood, Robin" sort="Wood, Robin" uniqKey="Wood R" first="Robin" last="Wood">Robin Wood</name><affiliation><nlm:aff id="d31e123">Desmond Tutu HIV Centre, Institute of Infectious Diseases & Molecular Medicine, University of Cape Town, Cape Town, South Africa;</nlm:aff></affiliation><affiliation><nlm:aff id="d31e123">Department of Medicine, University of Cape Town, Cape Town, South Africa;</nlm:aff></affiliation></author></analytic><series><title level="j">American Journal of Respiratory and Critical Care Medicine</title><idno type="ISSN">1073-449X</idno><idno type="eISSN">1535-4970</idno><imprint><date when="2010">2010</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><italic>Rationale</italic>: In 2005, we reported high prevalence of untreated pulmonary tuberculosis (TB) in a South African community. Prevalent untreated TB is the main source of transmission. In settings with large burdens of human immunodeficiency virus (HIV) and TB, highly active antiretroviral therapy (HAART) may contribute to TB control.</p><p><italic>Objectives</italic>: To assess the community-level impact of HAART on TB prevalence, we repeated a community-based TB prevalence cross-sectional survey in 2008 following HAART roll-out.</p><p><italic>Methods</italic>: A random 10% adult population sample was identified from the community. Participants provided two sputum specimens for acid-fast bacilli microscopy and TB culture. Oral transudate specimen was collected for anonymous HIV testing, linked to TB diagnosis. An interviewer-administered, structured questionnaire identified TB and HIV history and risk factors.</p><p><italic>Measurements and Main Results</italic>: In the 2008 survey, 1,250 adults participated (90% response rate); 306 (25%) tested HIV positive, of which 60 (20%) were receiving HAART. A total of 20 TB cases were identified (12 receiving TB treatment), representing a significant decline in prevalence from 3.2 to 1.6% (<italic>P</italic> = 0.02) between the surveys. TB prevalence in participants not infected with HIV was unchanged (<italic>P</italic> = 0.90). The decline occurred among participants not infected with HIV, decreasing from 9.2 to 3.6% in 2005 to 2008, respectively (<italic>P</italic> = 0.003). In participants infected with HIV, prevalence of treated TB declined from 4 to 2.3% (<italic>P</italic> = 0.06), and untreated TB prevalence from 5.2 to 1.3% (<italic>P</italic> = 0.02). The proportion of untreated TB in patients receiving HAART decreased significantly, from 22 to 0% (<italic>P</italic> < 0.001).</p><p><italic>Conclusions</italic>: Prevalence of undiagnosed TB declined significantly over a period of increasing HAART availability. The decline was predominantly in individuals infected with HIV receiving HAART.</p></div></front></TEI><pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Am J Respir Crit Care Med</journal-id><journal-id journal-id-type="publisher-id">ajrccm</journal-id><journal-title-group><journal-title>American Journal of Respiratory and Critical Care Medicine</journal-title></journal-title-group><issn pub-type="ppub">1073-449X</issn><issn pub-type="epub">1535-4970</issn><publisher><publisher-name>American Thoracic Society</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">20558626</article-id><article-id pub-id-type="pmc">2970849</article-id><article-id pub-id-type="publisher-id">ajrccm18281080</article-id><article-id pub-id-type="doi">10.1164/rccm.201004-0598OC</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>E. Tuberculosis and Mycobacterial Disease</subject></subj-group></article-categories><title-group><article-title>Antiretroviral Program Associated with Reduction in Untreated Prevalent Tuberculosis in a South African Township</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Middelkoop</surname><given-names>Keren</given-names></name><xref ref-type="aff" rid="d31e123">1</xref><xref ref-type="aff" rid="d31e123">2</xref></contrib><contrib contrib-type="author"><name><surname>Bekker</surname><given-names>Linda-Gail</given-names></name><xref ref-type="aff" rid="d31e123">1</xref><xref ref-type="aff" rid="d31e123">2</xref></contrib><contrib contrib-type="author"><name><surname>Myer</surname><given-names>Landon</given-names></name><xref ref-type="aff" rid="d31e123">3</xref><xref ref-type="aff" rid="d31e123">4</xref></contrib><contrib contrib-type="author"><name><surname>Whitelaw</surname><given-names>Andrew</given-names></name><xref ref-type="aff" rid="d31e123">5</xref><xref ref-type="aff" rid="d31e123">6</xref></contrib><contrib contrib-type="author"><name><surname>Grant</surname><given-names>Alison</given-names></name><xref ref-type="aff" rid="d31e123">7</xref></contrib><contrib contrib-type="author"><name><surname>Kaplan</surname><given-names>Gilla</given-names></name><xref ref-type="aff" rid="d31e123">8</xref></contrib><contrib contrib-type="author"><name><surname>McIntyre</surname><given-names>James</given-names></name><xref ref-type="aff" rid="d31e123">9</xref></contrib><contrib contrib-type="author"><name><surname>Wood</surname><given-names>Robin</given-names></name><xref ref-type="aff" rid="d31e123">1</xref><xref ref-type="aff" rid="d31e123">2</xref></contrib></contrib-group><aff id="d31e123"><label>1</label>Desmond Tutu HIV Centre, Institute of Infectious Diseases & Molecular Medicine, University of Cape Town, Cape Town, South Africa;<label>2</label>Department of Medicine, University of Cape Town, Cape Town, South Africa;<label>3</label>Centre for Infectious Diseases Epidemiology & Research, School of Public Health & Family Medicine, University of Cape Town, Cape Town, South Africa;<label>4</label>International Centre for AIDS Care and Treatment Programs, and Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York;<label>5</label>National Health Laboratory Service, Cape Town, South Africa;<label>6</label>Division of Medical Microbiology, Department of Clinical Laboratory Sciences, University of Cape Town, Cape Town, South Africa;<label>7</label>London School of Hygiene and Tropical Medicine, London, United Kingdom;<label>8</label>Laboratory of Mycobacterial Immunity and Pathogenesis, the Public Health Research Institute, University of Medicine and Dentistry of New Jersey, Newark, New Jersey; and<label>9</label>Anova Health Institute, Johannesburg, South Africa</aff><author-notes><corresp>Correspondence and requests for reprints should be addressed to Keren Middelkoop, MBChB, P.O. Box 13801 Mowbray 7705, Cape Town, RSA. E-mail: <email>keren.middelkoop@hiv-research.org.za</email></corresp></author-notes><pub-date pub-type="ppub"><day>15</day><month>10</month><year>2010</year></pub-date><pub-date pub-type="epub"><day>17</day><month>6</month><year>2010</year></pub-date><volume>182</volume><issue>8</issue><fpage>1080</fpage><lpage>1085</lpage><history><date date-type="received"><day>16</day><month>4</month><year>2010</year></date><date date-type="accepted"><day>16</day><month>6</month><year>2010</year></date></history><permissions><copyright-statement>Copyright © 2010, American Thoracic Society</copyright-statement><copyright-year>2010</copyright-year></permissions><self-uri xlink:title="pdf" xlink:href="AJRCCM18281080.pdf"></self-uri><abstract><p><italic>Rationale</italic>: In 2005, we reported high prevalence of untreated pulmonary tuberculosis (TB) in a South African community. Prevalent untreated TB is the main source of transmission. In settings with large burdens of human immunodeficiency virus (HIV) and TB, highly active antiretroviral therapy (HAART) may contribute to TB control.</p><p><italic>Objectives</italic>: To assess the community-level impact of HAART on TB prevalence, we repeated a community-based TB prevalence cross-sectional survey in 2008 following HAART roll-out.</p><p><italic>Methods</italic>: A random 10% adult population sample was identified from the community. Participants provided two sputum specimens for acid-fast bacilli microscopy and TB culture. Oral transudate specimen was collected for anonymous HIV testing, linked to TB diagnosis. An interviewer-administered, structured questionnaire identified TB and HIV history and risk factors.</p><p><italic>Measurements and Main Results</italic>: In the 2008 survey, 1,250 adults participated (90% response rate); 306 (25%) tested HIV positive, of which 60 (20%) were receiving HAART. A total of 20 TB cases were identified (12 receiving TB treatment), representing a significant decline in prevalence from 3.2 to 1.6% (<italic>P</italic> = 0.02) between the surveys. TB prevalence in participants not infected with HIV was unchanged (<italic>P</italic> = 0.90). The decline occurred among participants not infected with HIV, decreasing from 9.2 to 3.6% in 2005 to 2008, respectively (<italic>P</italic> = 0.003). In participants infected with HIV, prevalence of treated TB declined from 4 to 2.3% (<italic>P</italic> = 0.06), and untreated TB prevalence from 5.2 to 1.3% (<italic>P</italic> = 0.02). The proportion of untreated TB in patients receiving HAART decreased significantly, from 22 to 0% (<italic>P</italic> < 0.001).</p><p><italic>Conclusions</italic>: Prevalence of undiagnosed TB declined significantly over a period of increasing HAART availability. The decline was predominantly in individuals infected with HIV receiving HAART.</p></abstract><kwd-group><kwd>tuberculosis</kwd><kwd>prevalence</kwd><kwd>human immunodeficiency virus</kwd><kwd>antiretroviral therapy</kwd></kwd-group></article-meta><notes><fn-group><fn><p>Supported by National Institutes of Health (NIH) CIPRA (Comprehensive Integrated Program of Research on AIDS) grant 1 U19AI053217 (K.M., L.G.B., and R.W), NIH CIPRA grant 1 U19AI05321 and NIH RO1 grant AI058736–02 (R.W. and J.M.) and NIH R01 grant AI54361 (G.K.).</p></fn><fn><p>The content of this publication does not necessarily reflect the views or policies of the National Institute of Allergy and Infectious Diseases, nor does mention of trade names, commercial projects, or organizations imply endorsement by the U.S. Government.</p></fn><fn><p>Originally Published in Press as DOI: 10.1164/rccm.201004-0598OC on June 25, 2010</p></fn><fn><p><bold><italic>Author Disclosure</italic>:</bold> K.M. received more than $100,001 from the National Institutes of Health (NIH) in sponsored grants for the Comprehensive Integrated Program of Research on AIDS, South Africa (CIPRA-SA); L.-G.B. received more than $100,001 from the NIH in sponsored grants for the CIPRA-SA; L.M. received $10,001–$50,000 from the NIH for various grants (R01, etc.); A.W. received up to $1,000 from Merck, Sharpe, & Dohme in lecture fees for nonpromotional continuing medical education; A.G. received up to $1,000 from the NIH in sponsored grants; G.K. received $10,001–$50,000 from the Celegene Corporation as a board member, and holds more than $100,001 in options accumulated over a number of years from the Celgene Corporation; J.M. received $1,001–$5,000 from Abbott in speakers fees, more than $100,001 from the NIH in sponsored grants for the CIPRA-SA and International Maternal Pediatric Adolescent AIDS Clinical Trials, $10,001–$50,000 from UNITAID as chair of proposal review committee, and up to $1,000 from the World Health Organization as a Prevention of Mother To Child Transmission guideline committee chair; J.M.'s institution received more than $100,001 from the NIH in research grants; R.W. received more than $100,001 from the NIH in sponsored grants (including CIPRA-SA).</p></fn></fn-group></notes></front>
</pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaSubSaharaV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001478 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 001478 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaSubSaharaV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.32. |  |